Characteristics and Outcomes of Adult Patients Lost to Follow-Up at an Antiretroviral Treatment Clinic in Johannesburg, South Africa
- 1 January 2008
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 47 (1) , 101-107
- https://doi.org/10.1097/qai.0b013e31815b833a
Abstract
A significant proportion of those initiating antiretroviral treatment (ART) for HIV infection are lost to follow-up. Causes for discontinuing ART follow-up in resource-limited settings are not well understood. A retrospective analysis was conducted of all adult patients receiving ART at an urban public clinic in Johannesburg, South Africa between April 2004 and June 2005. Patients discontinuing follow-up for at least 6 weeks were identified and further studied, and causes for treatment default were tabulated. Of 1631 adult patients studied, 267 (16.4%) discontinued follow-up during the study period. Gender, ethnicity, and age were not predictive of loss to follow-up. Of those discontinuing follow-up, 173 (64.8%) were successfully traced. Death accounted for 48% (n = 83) of those traced. Characteristics associated with death were older age at ART initiation (P = 0.022), lower baseline CD4 cell count (P = 0.0073), higher initial HIV RNA load (P = 0.024), and loss of weight on ART (P = 0.033). Date of death was known for 71% (n = 59) of patients traced deceased, of whom 83% (n = 49) had died within 30 days of active ART. Common nonmortality losses included relocation or clinic transfer (25.4%) and hospitalization or illness not resulting in death (10.4%). Few cited financial difficulty or medication toxicity as reasons for discontinuing follow-up. Nearly 1 in 6 patients receiving ART in a resource-constrained setting had discontinued follow-up over a 15-month period. Early mortality was high, especially in those with profound immunosuppression. Improving access to care and streamlining patient tracking may improve ART outcomes.Keywords
This publication has 36 references indexed in Scilit:
- Bevacizumab for Graft RejectionOphthalmology, 2007
- Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, UgandaAIDS, 2007
- Motivations and Methods for Self-disclosure of HIV Seropositivity in Nairobi, KenyaAIDS and Behavior, 2007
- Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)British Journal of Ophthalmology, 2006
- Effect of antiretroviral treatment and counselling on disclosure of HIV-serostatus in Johannesburg, South AfricaAIDS Care, 2006
- Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western KenyaAIDS, 2006
- Evaluation of antiretroviral therapy results in a resource‐poor setting in Blantyre, MalawiTropical Medicine & International Health, 2005
- The Case for Earlier Treatment of HIV InfectionClinical Infectious Diseases, 2004
- Inhibition of Hemangiogenesis and LymphangiogenesisafterNormal-Risk Corneal Transplantation by Neutralizing VEGF Promotes Graft SurvivalInvestigative Opthalmology & Visual Science, 2004
- Human herpes simplex virus keratitis: the pathogenesis revisitedOcular Immunology and Inflammation, 2004